MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 145712 | Name: CI-949

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CI-949 is a novel antiallergy compound that has been studied for its potential therapeutic effects, particularly in the treatment of allergic reactions and immune function modulation. CI-949 has shown inhibition of allergic reactions, such as the release of histamine, leukotrienes, and thromboxane B2 from human leukocytes and mast cells. CI-949 appears to be a py agent, with the ability to inhibit allergic reactions and modulate immune responses.

Chemical Structure

CI-949
CI-949
CAS#104961-19-5

Theoretical Analysis

MedKoo Cat#: 145712

Name: CI-949

CAS#: 104961-19-5

Chemical Formula: C20H20N6O3

Exact Mass: 392.1600

Molecular Weight: 392.42

Elemental Analysis: C, 61.22; H, 5.14; N, 21.42; O, 12.23

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
CI-949; CI949; CI 949;
IUPAC/Chemical Name
3-isopropoxy-5-methoxy-1-phenyl-N-(1H-tetrazol-5-yl)-1H-indole-2-carboxamide
InChi Key
JPTSIWRGXIZEOO-UHFFFAOYSA-N
InChi Code
1S/C20H20N6O3/c1-12(2)29-18-15-11-14(28-3)9-10-16(15)26(13-7-5-4-6-8-13)17(18)19(27)21-20-22-24-25-23-20/h4-12H,1-3H3,(H2,21,22,23,24,25,27)
SMILES Code
COC1=CC2=C(C=C1)N(C(C(=O)NC3=NN=NN3)=C2OC(C)C)C4=CC=CC=C4
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 392.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Houston BJ, Macallum GE, Walker RM, Albassam MA, Gough A, Smith GS. Toxicity of CI-949, a novel anti-allergy agent. Fundam Appl Toxicol. 1993 Oct;21(3):376-83. doi: 10.1006/faat.1993.1110. PMID: 8258391. 2: Bleavins MR, Martin RA, de la Iglesia FA, Munson AE, McCay JA, Fouant MM, White KL Jr. Effects of CI-949, a novel antiallergy compound, on host resistance in mice. Fundam Appl Toxicol. 1991 Nov;17(4):723-32. doi: 10.1016/0272-0590(91)90180-c. PMID: 1778359. 3: Koller LD, Voller BE, Hedstrom OR, Steppan LG, Kerkvliet NI, Thueson DO. Effect of CI-949 and CI-959 on immune function and lymphoid organs in rats. Int J Immunopharmacol. 1989;11(5):509-16. doi: 10.1016/0192-0561(89)90180-x. PMID: 2807627. 4: Adolphson RL, Thueson DO, Finkel MP, Chestnut JC, Conroy MC. CI-949: a new, potential antiallergy compound inhibits antigen-induced allergic reactions in guinea-pigs in vitro and in vivo. Pulm Pharmacol. 1990;3(4):203-8. doi: 10.1016/0952-0600(90)90018-e. PMID: 1966908. 5: Branche AR, Rouphael NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Malkin E, Bethony JM, Walsh EE, Graciaa DS, Samaha H, Sherman AC, Walsh SR, Abate G, Oikonomopoulou Z, El Sahly HM, Martin TCS, Rostad CA, Smith MJ, Ladner BG, Porterfield L, Dunstan M, Wald A, Davis T, Atmar RL, Mulligan MJ, Lyke KE, Posavad CM, Meagher MA, Stephens DS, Neuzil KM, Abebe K, Hill H, Albert J, Lewis TC, Giebeig LA, Eaton A, Netzl A, Wilks SH, Türeli S, Makhene M, Crandon S, Lee M, Nayak SU, Montefiori DC, Makowski M, Smith DJ, Roberts PC, Beigel JH; COVAIL Study Group. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses. medRxiv [Preprint]. 2022 Jul 15:2022.07.12.22277336. doi: 10.1101/2022.07.12.22277336. PMID: 35898343; PMCID: PMC9327623. 6: Eltorai AEM, Baird GL, Pangborn J, Eltorai AS, Antoci V Jr, Paquette K, Connors K, Barbaria J, Smeals KJ, Riley B, Patel SA, Agarwal S, Healey TT, Ventetuolo CE, Sellke FW, Daniels AH. Financial Impact of Incentive Spirometry. Inquiry. 2018 Jan-Dec;55:46958018794993. doi: 10.1177/0046958018794993. PMID: 30175643; PMCID: PMC6122234. 7: Bleavins MR, de la Iglesia FA, Munson AE, McCay JA, Stern ML, Fuchs BA, White KL Jr. Effects of CI-949, a novel antiallergy agent, on immune function of male Fischer 344 rats. J Pharmacol Exp Ther. 1991 Apr;257(1):316-22. PMID: 2019994. 8: Conroy MC, Kennedy JA, Chestnut JC, Wright CD, Adolphson RL, Thueson DO. Inhibition of histamine, leukotriene C4/D4, and thromboxane B2 release from human leukocytes and human chopped lung mast cells by the allergic mediator release inhibitor, CI-949. J Allergy Clin Immunol. 1990 Dec;86(6 Pt 1):902-8. doi: 10.1016/s0091-6749(05)80153-8. PMID: 1702129. 9: Wright CD, Kuipers PJ, Hoffman MD, Thueson DO, Conroy MC. Inhibition of human neutrophil activation by the allergic mediator release inhibitor, CI-949: mechanism of inhibitory activity. Biochem Biophys Res Commun. 1990 Mar 16;167(2):828-34. doi: 10.1016/0006-291x(90)92100-e. PMID: 2322255. 10: Goltermann J, Meinert S, Hülsmann C, Dohm K, Grotegerd D, Redlich R, Waltemate L, Lemke H, Thiel K, Mehler DMA, Enneking V, Borgers T, Repple J, Gruber M, Winter N, Hahn T, Brosch K, Meller T, Ringwald KG, Schmitt S, Stein F, Pfarr JK, Krug A, Nenadić I, Kircher T, Opel N, Dannlowski U. Temporal stability and state-dependence of retrospective self-reports of childhood maltreatment in healthy and depressed adults. Psychol Assess. 2023 Jan;35(1):12-22. doi: 10.1037/pas0001175. Epub 2022 Nov 10. PMID: 36355690. 11: Wright CD, Stewart SF, Kuipers PJ, Hoffman MD, Thueson DO, Conroy MC. Inhibition of human neutrophil activation by the allergic mediator release inhibitor, CI-949. J Leukoc Biol. 1991 Jan;49(1):58-64. doi: 10.1002/jlb.49.1.58. PMID: 1845811. 12: Wright CD, Devall LJ, Aker DO, Thueson DO, Conroy MC. Differential regulation of the activation of human eosinophils, macrophages, and neutrophils: effect of the allergic mediator release inhibitor CI-949. Agents Actions. 1990 Aug;31(1-2):11-5. doi: 10.1007/BF02003215. PMID: 2178315. 13: Gilbertsen RB, Cullinen KM, Wilburn DJ, Dong MK, Conroy MC. In vitro effects of the antiallergy compound, CI-949, on interleukin-1 and 2 release, and on mitogen and alloantigen responsiveness. Agents Actions. 1989 Jun;27(3-4):303-5. doi: 10.1007/BF01972805. PMID: 2529741. 14: Unangst PC, Connor DT, Stabler SR, Weikert RJ, Carethers ME, Kennedy JA, Thueson DO, Chestnut JC, Adolphson RL, Conroy MC. Novel indolecarboxamidotetrazoles as potential antiallergy agents. J Med Chem. 1989 Jun;32(6):1360-6. doi: 10.1021/jm00126a036. PMID: 2470904. 15: Yi Y, Liu J, Zhang Y, Zeng B, Lin L, Li C, Yang F, Zhang H, Xie R, Huang Z, Kang M, Jiang Y. Effectiveness of Lanzhou Lamb Rotavirus Vaccine and RotaTeq Against Hospitalized Rotavirus Infections Among Children During 2020-2023 in Guangdong Province, China: A Test-Negative Case-Control Study. Infect Dis Ther. 2024 Nov;13(11):2301-2317. doi: 10.1007/s40121-024-01040-y. Epub 2024 Sep 16. PMID: 39283583; PMCID: PMC11499462. 16: Liu Y, Weinberg MS, Ortega LS, Painter JA, Maloney SA. Overseas screening for tuberculosis in U.S.-bound immigrants and refugees. N Engl J Med. 2009 Jun 4;360(23):2406-15. doi: 10.1056/NEJMoa0809497. Erratum in: N Engl J Med. 2009 Jul 23;361(4):431. PMID: 19494216.

View History

CI 992

CI 992